Cyanotech Corporation (CYAN) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
Market cap $3.59M is the value of all shares combined.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCyanotech Corporation (CYAN) trades at $0.4857. Cyanotech Corporation cultivates, produces, and sells natural products derived from microalgae, including BioAstin Hawaiian Astaxanthin and Hawaiian Spirulina Pacifica. Market cap: $3.59M, Sector: Consumer defensive.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for CYAN: CYAN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CYAN against Consumer Defensive peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CYAN: 2/2 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Cyanotech Corporation (CYAN) Consumer Business Overview
Cyanotech Corporation, founded in 1983, specializes in microalgae-derived products like BioAstin and Spirulina, catering to the health and wellness market. With a focus on dietary supplements, the company distributes through diverse channels, including online, retail, and bulk sales, positioning itself within the competitive packaged foods sector.
What Is the Investment Thesis for CYAN?
Cyanotech Corporation presents a unique investment proposition within the consumer defensive sector, specifically in the niche market of microalgae-derived health supplements. The company's focus on BioAstin and Spirulina products caters to the growing demand for natural antioxidants and dietary supplements. However, with a negative P/E ratio of -1.35 and a negative profit margin of -7.1%, the company's current profitability is a concern. The gross margin of 32.1% indicates potential for improvement in operational efficiency. Key growth catalysts include expanding distribution channels and increasing consumer awareness of the health benefits of astaxanthin and spirulina. The company's low beta of -0.21 suggests relatively low volatility compared to the market, but investors should carefully consider the risks associated with OTC-traded companies.
Based on FMP financials and quantitative analysis
CYAN Key Highlights
Gross Margin of 32.1% indicates potential for profitability improvements through operational efficiencies.
- Negative Profit Margin of -7.1% signals challenges in achieving sustainable profitability.
- Market Cap of $3.59M reflects the company's small size and potential for growth or volatility.
- P/E Ratio of -1.35 indicates the company is currently not profitable, requiring further investigation into its earnings potential.
- Beta of -0.21 suggests the stock is less volatile than the market, potentially offering stability in turbulent times.
Who Are CYAN's Competitors?
CYAN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ASPU Aspen Group, Inc. | $0.23 | -0.13% | $7.24M | — |
| JVA Coffee Holding Co., Inc. | $3.44 | +0.29% | $19.6M | 775-pillar |
| WYHG Wing Yip Food Holdings Group Limited | $4.52 | -9.24% | $56.9M | 499-signal |
| LFVN LifeVantage Corporation | $6.37 | -2.15% | $80.4M | 615-pillar |
| FTLF FitLife Brands, Inc. | $9.22 | -3.05% | $86.6M | 605-pillar |
| SDSYA South Dakota Soybean Processors, LLC | $7.10 | 0.00% | $216M | 459-signal |
| NATR Nature's Sunshine Products, Inc. | $13.60 | -0.44% | $239M | 455-pillar |
| BGS B&G Foods, Inc. | $3.21 | -0.31% | $261M | 435-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are CYAN's Key Strengths?
Established brand recognition for BioAstin and Spirulina.
- Proprietary cultivation and extraction processes.
- Direct-to-consumer sales channel.
- Unique Hawaiian origin provides a marketing advantage.
What Are CYAN's Weaknesses?
Negative profit margin.
- Limited financial resources compared to larger competitors.
- Reliance on a small number of key products.
- Vulnerability to fluctuations in raw material costs.
What Could Drive CYAN Stock Higher?
Expansion of online sales channels to reach a broader customer base.
- Strategic partnerships with retailers and distributors to increase market reach.
- Product innovation and development of new formulations.
- International market expansion to tap into new sources of revenue.
- Increased consumer awareness and education campaigns to drive demand.
What Are the Key Risks for CYAN?
Financial-distress signal — its Altman Z-Score of -0.20 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-20.0%) — the business is not currently generating profit on shareholder capital.
- Increased competition from larger nutraceutical companies.
- Changes in regulatory requirements for dietary supplements.
- Fluctuations in raw material prices.
- Negative publicity regarding the safety or efficacy of astaxanthin or spirulina.
- Negative profit margin and limited financial resources.
What Are the Growth Opportunities for CYAN?
- Expansion of Online Sales Channels: Cyanotech can capitalize on the growing e-commerce trend by expanding its online sales channels. By investing in its online presence, improving its website user experience, and leveraging digital marketing strategies, Cyanotech can reach a broader customer base and increase sales. This includes direct-to-consumer sales and partnerships with online retailers. Timeline: Ongoing.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with major retailers and distributors can significantly expand Cyanotech's market reach. Collaborating with established players in the health and wellness industry can provide access to new markets and customer segments. This includes partnerships with grocery chains, pharmacies, and specialty health stores. Timeline: Ongoing.
- Product Innovation and New Product Development: Investing in research and development to create new and innovative products can drive growth. This includes exploring new applications for astaxanthin and spirulina, as well as developing new formulations and delivery methods. The market for innovative dietary supplements is constantly evolving, and Cyanotech can stay ahead of the curve by introducing novel products that meet consumer needs. Timeline: Ongoing.
- International Market Expansion: Expanding into international markets represents a significant growth opportunity for Cyanotech. The global dietary supplements market is growing rapidly, particularly in emerging economies. By targeting specific regions with tailored marketing strategies and distribution networks, Cyanotech can tap into new sources of revenue and diversify its customer base. Timeline: Ongoing.
- Increased Consumer Awareness and Education: Investing in consumer education and awareness campaigns can drive demand for Cyanotech's products. Many consumers are not fully aware of the health benefits of astaxanthin and spirulina. By educating consumers about the science behind these ingredients and their potential health benefits, Cyanotech can increase demand and build brand loyalty. This includes content marketing, social media engagement, and partnerships with health influencers. Timeline: Ongoing.
What Are CYAN's Competitive Advantages?
- Proprietary cultivation and extraction processes.
- Established brand recognition for BioAstin and Spirulina.
- Location in Hawaii provides a unique selling proposition (USP).
- Long-standing relationships with distributors and retailers.
What Does CYAN Do?
Cyanotech Corporation, established in 1983 and headquartered in Kailua-Kona, Hawaii, focuses on the cultivation, production, and sale of natural products derived from microalgae. The company's flagship products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant known for enhancing skin health and supporting eye, joint, and immune function. This product is marketed as a human dietary supplement and dietary ingredient. Another key product is Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement, promoted for its energy-boosting, immune-strengthening, and cardiovascular benefits, as well as its antioxidant carotenoid content. Cyanotech distributes its products through a variety of channels, including distributors, retailers, and online platforms, directly targeting consumers. Additionally, the company engages in bulk sales to manufacturers, formulators, and distributors within the health foods, nutraceuticals, and dietary supplement industries. The company also provides contract extraction services. Cyanotech's commitment to producing high-quality, microalgae-based products has allowed it to establish a presence in the competitive health and wellness market.
What Products and Services Does CYAN Offer?
- Cultivates and produces microalgae.
- Extracts and processes astaxanthin from microalgae.
- Manufactures and packages dietary supplements.
- Sells BioAstin Hawaiian Astaxanthin for skin, eye, joint, and immune health.
- Sells Hawaiian Spirulina Pacifica for energy, immune support, and cardiovascular benefits.
- Provides contract extraction services.
How Does CYAN Make Money?
- Cultivation and production of microalgae-derived products.
- Direct-to-consumer sales through online channels.
- Sales through distributors and retailers.
- Bulk sales to manufacturers and formulators.
What Industry Does CYAN Operate In?
Cyanotech Corporation operates within the consumer defensive sector, specifically in the packaged foods industry, focusing on dietary supplements. The global dietary supplements market is experiencing steady growth, driven by increasing health awareness and an aging population. Key trends include the rising demand for natural and organic products, as well as the growing popularity of online retail channels. Cyanotech faces competition from other players in the nutraceuticals market. Competitors include companies that offer similar algae-based products and broader dietary supplement brands. The company's success depends on its ability to differentiate its products through quality, branding, and effective marketing.
Who Are CYAN's Key Customers?
- Health-conscious consumers seeking natural supplements.
- Individuals looking for antioxidant and immune support.
- Manufacturers and formulators in the health foods and nutraceuticals industries.
- Retailers and distributors in the dietary supplement market.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 40 |
| 2026-08-26 | 40 |
| 2026-08-29 | 40 |
| 2026-09-01 | 40 |
| 2026-09-04 | 40 |
| 2026-09-07 | 40 |
| 2026-09-10 | 40 |
What changed?
The score has stayed at 40.
Over the same 18 days the stock moved +13.3%.
Insider Activity
The most recent 11 insider filings for Cyanotech Corporation break down as 4 sales and 7 purchases. On net that is roughly 200K shares acquired (about $14K) — insiders putting money in tends to read as conviction.
Quarterly Financial Performance: Cyanotech Corporation
Revenue for Cyanotech Corporation came in at $6.5M during Q1 FY2027, a 18.3% contraction versus the preceding quarter. The company recorded net income of $288K, with diluted EPS of $0.04. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Consumer Defensive. Across the four most recent quarters, CYAN averaged $-0.00 in diluted EPS.
CYAN Valuation & Market Position
With a $3.59M market cap, Cyanotech Corporation sits in the micro-cap segment of the market.
Key Financial Metrics
Return on equity for Cyanotech Corporation stands at -20.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -2.5%, showing how much profit it generates from its asset base. A current ratio of 1.00 indicates the company holds enough short-term assets to cover its near-term obligations.
Financial Health
Cyanotech Corporation's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.20 places it in the distress zone, a signal of elevated financial risk.
Earnings Track Record
Cyanotech Corporation has missed Wall Street's EPS estimate in 3 of its last 3 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 112.0% below estimates on average.
Company Profile
Cyanotech Corporation operates in the Packaged Foods industry within the Consumer Defensive sector. It is headquartered in Kailua-Kona, US. The company is led by CEO Matthew Keith Custer. CYAN has traded publicly since 1991.
CYAN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Established brand recognition for BioAstin and Spirulina.
- Proprietary cultivation and extraction processes.
- Direct-to-consumer sales channel.
- Unique Hawaiian origin provides a marketing advantage.
Bear Case
- Negative profit margin.
- Limited financial resources compared to larger competitors.
- Reliance on a small number of key products.
- Vulnerability to fluctuations in raw material costs.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 FY2027 | $6M | $288,000 | $0.04 |
| Q4 FY2026 | $8M | -$128,000 | -$0.02 |
| Q3 FY2026 | $6M | -$230,000 | -$0.03 |
| Q2 FY2026 | $7M | $1,000 | $0.0001 |
Q1 FY2027 · filed 30 Jun 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
CYAN Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Aug 29, 2023
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Mar 23, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Sep 6, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Feb 10, 2022
CYAN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CYAN.
Price Targets
Wall Street price target analysis for CYAN.
CYAN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CYAN; grades run from A+ (80-100) to F (below 30).
Leadership: Matthew Keith Custer
CEO
Matthew Keith Custer serves as the CEO of Cyanotech Corporation, overseeing the company's operations and strategic direction. As CEO, he is responsible for managing the company's 77 employees and driving its growth in the competitive nutraceuticals market. His leadership is crucial for navigating the challenges and opportunities facing Cyanotech in the evolving health and wellness industry.
Track Record: Due to the limitations of the provided source data, specific achievements, strategic decisions, and company milestones under Matthew Keith Custer's leadership cannot be detailed. His tenure and impact on Cyanotech's performance require further investigation beyond the available information. Assessing his track record would involve analyzing the company's financial performance, product innovation, and market share growth during his time as CEO.
CYAN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Cyanotech Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited financial disclosure, which increases investment risk. Trading on the OTC Other market typically involves less stringent listing requirements compared to major exchanges like the NYSE or NASDAQ, resulting in potentially less transparency and regulatory oversight. Investors should exercise caution and conduct thorough due diligence before investing in companies on this tier.
- OTC Tier: OTC Other
- Limited financial disclosure due to the OTC Other tier.
- Lower trading volume and liquidity compared to major exchanges.
- Potential for wider bid-ask spreads.
- Increased price volatility.
- Less stringent regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's revenue and earnings growth potential.
- Analyze the company's cash flow and debt levels.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been in operation since 1983.
- Cyanotech has established brand recognition for BioAstin and Spirulina.
- The company has a direct-to-consumer sales channel.
- Cyanotech has a physical presence with its headquarters in Kailua-Kona, Hawaii.
What Investors Ask About Cyanotech Corporation (CYAN) — Consumer Defensive
Is CYAN a good stock?
Stock Expert AI does not rate CYAN buy, sell or hold. Cyanotech Corporation has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CYAN stock?
However, key valuation metrics such as the negative P/E ratio of -1.35 and the negative profit margin of -7.1% suggest that the company faces profitability challenges. The gross margin of 32.1% indicates potential for improvement.
What are the key factors to evaluate for CYAN?
Evaluate CYAN on fundamentals, analyst consensus, and risk factors. Market Cap of $3.59M reflects the company's small size and potential for growth or volatility. Not financial advice.
How frequently does CYAN data refresh on this page?
CYAN's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CYAN's recent stock price performance?
Cyanotech Corporation (CYAN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established brand recognition for BioAstin and Spirulina. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CYAN overvalued or undervalued right now?
Cyanotech Corporation (CYAN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CYAN?
Yes, most major brokerages offer fractional shares of Cyanotech Corporation (CYAN) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CYAN's earnings and financial reports?
Cyanotech Corporation (CYAN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CYAN earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC analysis based on general characteristics of the OTC Other tier.